High-throughput invitro profiling assays: lessons learnt from experiences at Novartis

Bibliography

• WANG J, URBAN L: The impact of early ADME profiling on drug discovery and development strategy. Drug Discov. World (2004) 5:73-86.
   Google Scholar
• CURATOLO W: Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Technol. Today (1998) 1(9):387-393.
   Google Scholar
• FALLER B: Improving solubility in lead optimization. Am. Pharm. Rev. (2004) 7(4):30-32.
   Google Scholar
• AVDEEF A: Physicochemical profiling. Curr. Topics Med. Chem. (2001) 1:277-351.
   PubMedGoogle Scholar
• BERGSTROM CAS, LUTHMAN K, ARTURSSON P: Accuracy of calculated pH-dependent aqueous drug solubility. Eur. J. Pharm. Sci. (2004) 22:387-398.
   PubMed Web of Science ®Google Scholar
• GLOMME A, MARZ J, DRESSMAN JB: Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J. Pharm. Sci. (2005) 94:1-16.
   PubMed Web of Science ®Google Scholar
• KERNS EH: High-throughput physicochemical profiling for drug discovery. J. Pharm. Sci. (2001) 90:1838-1858.
   PubMed Web of Science ®Google Scholar
• AVDEEF A: Absorption and drug development – solubility, permeability and charge state. Wiley-Interscience, Hoboken, New Jersey, USA (2003).
   Google Scholar
• LIPINSKY CA, LOMBARDO F, DOMINY BW et al.: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (1997) 23:3-25.
   Web of Science ®Google Scholar
• KIBBEY CE, POOLE SK, ROBINSON B et al.: An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. J. Pharm. Sci. (2001) 90:1164-1175.
   PubMed Web of Science ®Google Scholar
• BEVAN CD, LLOYD RS: A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. (2000) 72:1781-1787.
   PubMed Web of Science ®Google Scholar
• KARIV I, ROURICK RA, KASSEL DB et al.: Improvement of ‘hit-to-lead’ optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties. Comb. Chem. High Throughput Screen. (2002) 5:459-472.
   PubMed Web of Science ®Google Scholar
• STRESSER DM, BROUDY MI, HO T et al.: Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible. Drug Metab. Dispos. (2004) 32:105-112.
   PubMed Web of Science ®Google Scholar
• PAN L, HO Q, TSUTSUI K, TAKAHASHI L: Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J. Pharm. Sci. (2001) 90:521-529.
   PubMed Web of Science ®Google Scholar
• STOUCH TR, KENYON JR, JOHNSON SR et al.: In silico ADME/Tox: why models fail. J. Computer-Aided Mol. Des. (2003) 17:83-92.
   PubMed Web of Science ®Google Scholar
• EGAN W, MERT KM, BALDWIM JJ: Prediction of drug absorption using multivariate statistics. J. Med. Chem. (2000) 43:3867-3877.
   PubMed Web of Science ®Google Scholar
• ZHAO YH, LE J, ABRAHAM MH et al.: Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci. (2002) 91(2):605.
   Web of Science ®Google Scholar
• VALKO K, BEVAN C, REYNOLDS D: Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to Log P/Log D. Anal. Chem. (1997) 69(11):2022-2029.
   PubMed Web of Science ®Google Scholar
• ONG S, LIU H, PIDGEON C: Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J. Chromatogr. A (1996) 728(1-2):113-128.
   PubMed Web of Science ®Google Scholar
• KANSY M, SENNER F, GUBERNATOR K: Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. (1998) 41:1007-1010.
   PubMed Web of Science ®Google Scholar
• AVDEEF A, TSINMAN O: PAMPA – a drug absorption in vitro model. Eur. J. Pharm. Sci. (2006) 28(1-2):43-50.
   PubMed Web of Science ®Google Scholar
• LOWTHER N, TOMLINSON B, FOX R et al.: Caco-2 cell permeability and physicochemical properties of a new oral iron chelator. J. Pharm. Sci. (1998) 87:1041-1045.
   PubMed Web of Science ®Google Scholar
• WOHNSLAND F, FALLER B: High-throughput permeability pH profile and high-throughput alkane/water Log P with artificial membranes. J. Med. Chem. (2001) 44(6):923-930.
   PubMed Web of Science ®Google Scholar
• ARTURSSON P, KARLSSON J: Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human epithelial (Caco-2) cells. BioChem. Biophys. Res. Comm. (1991) 175(3):880-885.
   PubMed Web of Science ®Google Scholar
• YEE S: In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestine) absorption in man – fact or myth. Pharm. Res. (1997) 14(6):763-766.
   PubMed Web of Science ®Google Scholar
• HO NFH, ADSON A, BORCHARDT RT et al.: Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers. In: Transport Processes in Pharmaceutical Systems. Marcel Dekker, New York (USA), Basel (Switzerland) (2002):219-318.
   Google Scholar
• TAVELIN S, TAIPALENSUU J, SODERBERG L, MORRISON R, CHONG S, ARTURSSON P: Prediction of the oral absorption of low-permeability drugs using small intestine like 2/4/A1 cell monolayers. Pharm. Res. (2003) 20(3):397-405.
   PubMed Web of Science ®Google Scholar
• SAITOH R, SUGANO K, TAKATA N et al.: Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm. Res. (2004) 21(5):749-755.
   PubMed Web of Science ®Google Scholar
• SUGANO K, NORIYUKI T, MACHIDA M et al.: Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. Int. J. Pharm. (2002) 241:241-251.
   PubMed Web of Science ®Google Scholar
• SAWADA GA, BARSUHN CL, LUTZKE BS et al.: Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J. Pharm. Exp. Ther. (1999) 288:1317-1326.
   PubMed Web of Science ®Google Scholar
• AVDEEF A, ARTURSSON P, NEUHOFF S et al.: Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA pKa flux method. Eur. J. Pharm. Sci. (2005) 24(4):333-349.
   PubMed Web of Science ®Google Scholar
• MANDAGERE AK, THOMPSON TN, HWANG KK: Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J. Med. Chem. (2002) 45:304-311.
   PubMed Web of Science ®Google Scholar
• NARITOMI Y, TERASHITA S, KIMURA S, SUZUKI A, KAGAYAMA A, SUGIYAMA Y: Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. (2001) 29:1316-1324.
   PubMed Web of Science ®Google Scholar
• TANG W, WANG RW, LU AY: Utility of recombinant cytochrome P450 enzymes: a drug metabolism perspective. Curr. Drug Metab. (2005) 6:503-517.
   PubMed Web of Science ®Google Scholar
• RADOMINSKA-PANDYA A, BRATTON S, LITTLE JM: A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years. Curr. Drug Metab. (2005) 6:141-160.
   PubMed Web of Science ®Google Scholar
• LENGYEL G, VERES Z, SZABO P, VERECZKEY L, JEMNITZ K: Canilicular and sinusoidal disposition of bilirubin mono- and diglucuronides in sandwich-cultured human and rat primary hepatocytes. Drug Metab. Dispos. (2005) 33:1355-1360.
   PubMed Web of Science ®Google Scholar
• ANNAERT PP, BROUWER KL: Assessment of drug interactions in heptobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. (2005) 33:388-394.
   PubMed Web of Science ®Google Scholar
• REDDY A, HEIMBACH T, FREIWALD S et al.: Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J. Pharm. Biomed. Anal. (2005) 37:319.
   PubMed Web of Science ®Google Scholar
• MCGINNITY DF, SOARS MG, URBANOWICZ RA, RILEY RJ: Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. (2004) 32:1247-1253.
   PubMed Web of Science ®Google Scholar
• LIN JH, WONG BK: Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr. Drug Metab. (2002) 3:623-646.
   PubMed Web of Science ®Google Scholar
• MCDONNELL PJ, JACOBS MR: Hospital admissions resulting from preventable adverse drug reactions. Ann. Pharmacother. (2002) 36(9):1331-1336.
   PubMed Web of Science ®Google Scholar
• CURTIS LH, OSTBYE T, SENDERSKY V et al.: Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am. J. Med. (2003) 114(2):135-141.
   PubMed Web of Science ®Google Scholar
• DOUCET J, CHASSAGNE P, TRIVALLE C et al.: Drug–drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J. Am. Geriatr. Soc. (1996) 44(8):944-948.
   PubMed Web of Science ®Google Scholar
• SMITH DA, SCHMID EF: Drug withdrawals and the lessons within. Curr. Opin. Drug Discov. Dev. (2006) 9:38-46.
   PubMed Web of Science ®Google Scholar
• OBACH RS, WALSKY RL, VENKATAKRISHNAN K et al.: The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J. Pharmacol. Exp. Ther. (2006) 316(1):336-348.
   PubMed Web of Science ®Google Scholar
• BJORNSSON TD, CALLAGHAN JT, EINOLF HJ et al.: The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. (2003) 31(7):815-832.
   PubMed Web of Science ®Google Scholar
• TUCKER GT, HOUSTON JB, HUANG SM: Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – toward a consensus. Pharm Res. (2001) 18(8):1071-1080.
   PubMedGoogle Scholar
• BROWN HS, ITO K, GALETIN A et al.: Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol. (2005) 60(5):508-518.
   PubMed Web of Science ®Google Scholar
• OBACH RS, WALSKY RL, VENKATAKRISHNAN K et al.: In vitro cytochrome P450 inhibition data and the prediction of drug–drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin. Pharmacol. Ther. (2005) 78(6):582-592.
   PubMed Web of Science ®Google Scholar
• ROSTAMI-HODJEGAN A, TUCKER GT: ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions. Drug Disc. Today Technologies (2004) 1(4):441-444.
   PubMedGoogle Scholar
• CRESPI CL: Assessing the potential for drug–drug interactions in an accelerated throughput mode. PSTT (1999) 2:119-112.
   PubMedGoogle Scholar
• REDFERN WS, WAKEFIELD ID, PRIOR H et al.: Safety pharmacology – a progressive approach. Fund. Clin. Pharm. (2002) 16:161-173.
   PubMed Web of Science ®Google Scholar
• WHITEBREAD S, HAMON J, BOJANIC D et al.: In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today (2005) 10:1421-1433.
   PubMed Web of Science ®Google Scholar
• HAMON J, AZZAOUI K, WHITEBREAD S et al.: In vitro safety pharmacology profiling. Eur. J. Pharm. (2006) 1:60-63.
   Google Scholar
• REDFERN L, CARLSSON AS, DAVIS WG et al.: Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. (2003) 58:32-45.
   PubMed Web of Science ®Google Scholar
• VALENTIN P, HOFFMANN F, DE CLERCK TG et al.: Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods (2004) 49:171-181.
   PubMedGoogle Scholar
• HOFFMANN P, WARNER B: Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods (2006) 53(2):87-105.
   Google Scholar
• WEMPE MF: Quaternary ammonium ions can externally block voltage-gated K+ channels. Establishing a theoretical and experimental model that predicts KDS and the selectivity of K+ over Na+ ions. J. Mol. Struct. (2001) 562:63-78.
   Web of Science ®Google Scholar
• MURPHY SM, PALMER M, POOLE MF et al.: Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods (2006) 54(1):42-55.
   Google Scholar
• LEE WM: Drug-induced hepatotoxicity. New Engl. J. Med. (2003) 349:474-485.
   PubMed Web of Science ®Google Scholar
• GROENEBERG DA, GROSSE-SIESTRUP C, FISCHER A: In vitro models to study hepatotoxicity. Toxicol. Pathol. (2002) 30:394-399.
   PubMed Web of Science ®Google Scholar
• DAMBACH DM, ANDREWS BA, MOULIN F: New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. (2005) 33(1):17-26.
   Google Scholar
• BLOOM J: Principles of hematotoxicology: laboratory assessment and interpretation of data. Toxicol. Pathol. (1993) 21:130-134.
   PubMed Web of Science ®Google Scholar
• RICH IN : In vitro hematotoxicity testing in drug development: a review of past, present and future applications. Curr. Opin. Drug Discov. Dev. (2003) 6(1):100-109.
   PubMed Web of Science ®Google Scholar
• RICH IN, HALL KM: Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay. Toxicol. Sci. (2005) 87(2):427-441.
   PubMed Web of Science ®Google Scholar
• AMES BN, LEE F, DURSTON W: An improved bacterial system for the detection and classification of mutagens and carcinogens. Proc. Natl. Acad. Sci. USA (1973) 70:782-786.
   PubMed Web of Science ®Google Scholar
• FRIEAUFF W, POTTER-LOCHER F, CORDIER A et al.: Automatic analysis of the in vitro micronucleus test on V79 cells. Mutat. Res. (1998) 413:57-68.
   PubMed Web of Science ®Google Scholar
• FENECH M: Biomarkers of genetic damage for cancer epidemiology. Toxicology (2002) 181-182:411-416.
   PubMed Web of Science ®Google Scholar
• FLAMAND N, MEUNIER J, MEUNIER P et al.: Mutagenicity test: a miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. Toxicol. In Vitro (2001) 15:105-114.
   PubMed Web of Science ®Google Scholar
• KREJSA CM, HORVATH D, ROGALSKI SL et al.: Predicting ADME properties and side effects: the BioPrint approach. Curr. Opin. Drug Discov. Dev. (2003) 6(4):470-480.
   PubMed Web of Science ®Google Scholar
• FLIRI AF, LOGING WT, THADEIO PF et al.: Biological spectra analysis: linking biological activity profiles to molecular structure. Proc. Natl. Acad. Sci. USA (2005) 102:261-266.
   PubMed Web of Science ®Google Scholar